Disease amelioration by retinoids in various nephritic models has been reported from either immunological or pathophysiologic viewpoints. It has also been reported that retinoids exert immunosuppressive effects in a retinoic acid receptor (RAR)-␣-dependent manner. In particular, synthetic retinoid agonists with selectivity to RAR-␣ have been reported to have a remarkable disease-ameliorating effect in some immune disease models via their potent immunosuppressive activities; however, there has been no report in which the effect of RAR-␣-selective agonists in the nephritic models was examined. In this report, we investigated the effect of a newly synthesized RAR-␣-selective retinoid agonist, E6060 [4-{5-[7-fluoro-4-(trifluoromethyl)benzo[b]furan-2-yl]-1H-2-pyrrolyl}benzoic acid], on the disease progression in a murine lupus nephritis model. Female (NZBxNZW)F1 mice were prophylactically treated with E6060 from 5 months of age, and their nephritic (proteinuria, blood urea nitrogen) and immunological parameters (serum anti-DNA autoantibodies and total serum immunoglobulins) were monitored with age up to 10 months old. E6060 at 0.03 and 0.1 mg/kg (once daily, p.o.) significantly improved survival rate and prevented the development of proteinuria in (NZBxNZW)F1 mice. Anti-DNA autoantibodies and total serum IgG were also significantly reduced in the E6060-treated mice. Among IgG isotypes, IgG2a was substantially reduced by E6060 treatment, indicating reduced T helper 1 responses in E6060-treated mice. In accordance with this possibility, elevation of serum interleukin-12 (p40) in old female (NZBxNZW)F1 mice was significantly inhibited by E6060 treatment. Our data suggest that the RAR-␣-selective retinoid E6060 is a promising candidate of new remedy for lupus nephritis in systemic lupus erythematosus patients.Retinoids are vitamin A derivatives used for the treatment of vitamin A deficiency and dermatological disorders, as well as for chemoprophylaxis and therapy of certain cancers. Retinoids are ligands for retinoic acid receptor (RAR) and/or retinoid X receptor (RXR), both of which belong to the steroid receptor superfamily (Mangelsdorf and Evans, 1995). RAR and RXR each have three subtypes, ␣, , and ␥. Retinoids act by modulating the transcription of target genes through interaction with these RAR and RXR subtypes, thereby interfering with cellular regulation, growth, and differentiation processes.Retinoids, such as 4-hydroxyretinamide, all-trans-retinoic acid (ATRA), and 13-cis-retinoic acid, were reported to be effective in some immunological disease models, such as rat adjuvant arthritis (Brinckerhoff et al., 1983) and experimental allergic encephalomyelitis (Racke et al., 1995), which are believed to be caused through inappropriate cellular immune responses. Recently, Am80, a ligand with an affinity specific for RAR-␣, was reported to inhibit collagen-induced arthritis concomitantly with a prominent reduction in anti-collagen IgG titers (Kuwabara et al., 1996;Nagai et al., 1999). This report was the first...